Ipsen’s Dysport achieves first positive Phase III results for both episodic and chronic migraine, opening a new migraine therapy avenue
Executive summary: Ipsen reported positive topline Phase III results for Dysport in both episodic and chronic migraine prevention studies. It is the first botulinum toxin to demonstrate efficacy in both migraine types, potentially expanding Ipsen’s product portfolio and shifting market dynamics in migraine therapeutics.
Who is involved: Ipsen (manufacturer), Dysport (abobotulinumtoxinA), adult migraine patients, regulators such as the FDA and EMA.
Likely next: Ipsen will prepare regulatory submissions (or Application for regulatory filing, with FDA submission expected by Q4 2026 and EMA review slated for early 2027, followed by possible launch in 2028 if approved.
Ipsen announced that its Phase III BEOND program met primary endpoints for Dysport (abobotulinumtoxinA) in the prevention of episodic and chronic migraine in adults. This marks the first botulinum toxin to show positive topline data in both indications, positioning Dysport as a potential new option in the migraine prophylaxis market. The results could influence prescribing patterns and prompt competitive responses from rivals such as Allergan’s Botox.
Timeline
- — Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. (GlobeNewswire)
Analysis — what this means
Likely next events
- Ipsen plans to file a New Drug Application with the FDA by Q4 2026.
- EMA submission for Dysport in migraine is scheduled for early 2027.
- If approved, a US and EU launch could occur by mid‑2028.
Sectors affected
- Pharmaceuticals – migraine prophylaxis
- Botulinum toxin therapeutics
- Neurology drugs
Regulatory implications
- FDA will review under NDAs for botulinum toxin; decision expected within 10 months of filing.
- EMA will assess via centralised procedure; opinion anticipated ~12 months after submission.
Historical parallels
- OnabotulinumtoxinA (Botox) received FDA approval for chronic migraine in 2010.
- AbobotulinumtoxinA (Dysport) was approved for cervical dystonia in 2009.
Key entities
Sources
- Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. — GlobeNewswire